Bortezomib in relapsed or refractory myeloma patients

被引：0
|
作者：
Leonetti Crescenzi, S. [1 ]
Piccioni, A. L. [1 ]
Bagnato, A. [1 ]
机构：
[1] Osped Sandro Pertini, UOC Ematol, ASL Roma B, Rome, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [41] Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program
    Siegel, David S.
    Jagannath, Sundar
    Hajek, Roman
    Dimopoulos, Meletios A.
    Yoon, Sung-Soo
    Lonial, Sagar
    Laubach, Jacob P.
    Graef, Thorsten
    Pietrangelo, Dina
    Lupinacci, Lisa
    Reiser, David
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 813 - 814
  • [42] COMBINED VORINOSTAT AND BORTEZOMIB IN BORTEZOMIB-REFRACTORY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INTERIM ANALYSIS OF A PHASE IIB STUDY
    Siegel, D.
    Jagannath, S.
    Lonial, S.
    Dimopoulos, M.
    Yoon, S. S.
    Graef, T.
    Pitrangelo, D.
    Lupinacci, L.
    Reiser, D.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 156 - 157
  • [43] Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Richardson, Paul G.
    Guenther, Andreas
    Sezer, Orhan
    Siegel, David
    Blade, Joan
    LeBlanc, Richard
    Sutherland, Heather
    Sopala, Monika
    Mishra, Kaushal K.
    Mu, Song
    Bourquelot, Priscille M.
    Victoria Mateos, Maria
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3696 - +
  • [44] ENDEAVOR: carfilzomib superior to bortezomib in relapsed and refractory multiple myeloma
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (01) : 13 - 13
  • [45] Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma
    Ning, Yang-Min
    He, Kun
    Dagher, Ramz
    Sridhara, Rajeshwari
    Farrell, Ann T.
    Justice, Robert
    Pazdur, Richard
    ONCOLOGY-NEW YORK, 2007, 21 (12): : 1503 - 1508
  • [46] Pegylated liposomal doxorubicin and bortezomib in relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 453 - 455
  • [47] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [48] Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    Berenson, JR
    Jagannath, S
    Barlogie, B
    Siegel, DT
    Alexanian, R
    Richardson, PG
    Irwin, D
    Alsina, M
    Rajkumar, SV
    Srkalovic, G
    Singhal, S
    Limentani, S
    Niesvizky, R
    Esseltine, DL
    Trehu, E
    Schenkein, DP
    Anderson, K
    CANCER, 2005, 104 (10) : 2141 - 2148
  • [49] Economic evaluation of bortezomib (VELCADE) for relapsed and refractory multiple myeloma
    Bagust, A
    Haycox, AR
    Boland, A
    Chu, P
    Morgan, GJ
    Mota, REM
    Dubois, D
    Dhawan, R
    BLOOD, 2004, 104 (11) : 80A - 80A
  • [50] CLINICAL EFFICACY OF VELCADE (BORTEZOMIB) AND DEXAMETHASONE THERAPY IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA
    Ionita, I.
    Cheveresan, M.
    Calamar, D.
    Ionita, C.
    Oros, D.
    Ionita, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 627 - 628
12345